Natco reveals Revlimid patent challenge; Baxter warned on Aralast promotion;

@FiercePharma: Paper: Roche mulls 'massive' worldwide job cuts. News | Follow @FiercePharma

> Last week, Celgene said an unidentified company had launched a patent challenge on its blood-cancer drug Revlimid; that company is India's Natco Pharma, which has asked FDA to approve its version. Article

> The FDA has warned Baxter International against including what the agency called "misleading statements" in a brochure for the drug Aralast NP, which is used to treat an inherited condition that can hurt the lungs. Item

> Swedish pharma company Meda says it has agreed to buy U.S.-based Alaven Pharmaceutical for $350 million. Story

> Daiichi Sankyo, Japan's No.3 drugmaker, upgraded its revenue and profit outlook for the April-September first half thanks to strong earnings at its Indian unit Ranbaxy Laboratories. Item

> French drugmaker Ipsen posted a 7 percent rise in first-half earnings on the back of growing sales of specialty care drugs, such as those for treating cancer, and kept its goals for the year. News

> Kentucky Attorney General Jack Conway's office has reached a $3.75 million settlement between the state and GlaxoSmithKline over the alleged deceptive or false marketing of the drugmaker's anti-nausea medications, most notably Kytril and Zofran. News

> Cerbios-Pharma of Switzerland has officially opened its new high-potency active pharmaceutical ingredient manufacturing plant in Lugano. Report

Biotech News

 @FierceBiotech: Novartis set to begin late-stage testing of blood thinner. Article | Follow @FierceBiotech

 @JohnCFierce: Be sure to check out our Top 10 Women in Biotech report. Already getting plenty of suggestions for next year. Add yours. | Follow @JohnCFierce

> Achaogen wins $64 million biodefense contract. Article

> AMT looks for funding while it waits for EMA approval. Report

> Endo looks for more acquisitions. News

> Apixaban, Xarelto deliver good results in studies. Story

Biotech Research News

> Heart study finds long-term value in stem cell treatments. News

> Research scientists brace for layoffs as stimulus cash dries up. Report

> Scripps researchers piece together adenovirus structure. Item

> Muscle strength emerging as a major R&D focus. Story

> ESC advocates scramble to limit fallout from court ruling. Article

> Researchers turn mice into biosensors. News

Manufacturing News

> Ranbaxy may offer payment for FDA reset. Report

> Report to Obama: Target fill/finish to speed vax-making. News

> Weldon: Long ops fixes underway at J&J. Item

> Fakes report: Forget handbags, focus on drugs. Story

> Ops emphasis lets Pfizer extend product life. News

> Packaging reminds patients to take drugs. Article

And Finally... Research led by the Warwick Medical School at the University of Warwick has found that unhealthy glucose levels in patients with diabetes can cause significantly more problems for the body than just the well-known symptoms of the disease such as kidney damage and circulation problems. The raised glucose can also form what can be described as a sugar coating that can effectively smother and block the mechanisms our bodies use to detect and fight bacterial and fungal infections. Warwick release